glp 1 fgf21 agonist boehringer A peptide triple of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss Apollo signs near-$1B deal for

58 Phase 2a trial of GSBR-1290 (120mg) in 40 healthy obese volunteers over 8 weeks demonstrated a significant reduction in BW (120 mg: -4.74%

Berberine, Akkermansia, and probiotics get slapped with "GLP-1" labels but deliver mild natural support, not Ozempic-level resultscue reviews like "no change after 30 days." Hundreds of listings now hover at 2-3 stars as the hype-expectation gap widens

Chronic low-grade inflammation also has a major role in vascular aging, potentially leading to various age-related diseases, including cardiovascular diseases

The best read of the bunch is from Annals of Internal Medicine: Accurate Measurements of Gastric Emptying and Gastrointestinal Symptoms in the Evaluation of Glucagon-like Peptide-1 Receptor Agonists GI Symptoms: In clinical trials of GLP-1 RAs, GI symptoms are usually evaluated solely by participant self-report, which is unreliable

Chen said the most surprising finding to her was that so many of the websites were advertising something like reduced hair loss or improved sexual function when truly there's not substantial data to suggest that those are benefits that can be achieved by a GLP-1 RA. The advertising practices are problematic for patients, according to Reshma Ramachandran, MD, MPP, MHS, assistant professor of medicine (general medicine) and a co-author

Many of us in primary care and obesity medicine have similar anecdotes on our patients and hope to one day have a peer reviewed study of the benefit of GLPs in our rheumatoid patients. -Dr